Applied Molecular Evolution Report issue

For profit Phase 1
Founded: San Diego CA United States (1989)
Status: Acquired by Eli Lilly (2004)

Organization Overview

First Clinical Trial
2006
NCT00354926
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2008

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 1 Trials (2)

ocaratuzumab (1 trial)

tabalumab (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Lymphoma (Phase 1)

Lymphoma, Non-Hodgkin (Phase 1)

Multiple Myeloma (Phase 1)

Neoplasms, Plasma Cell (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 2
  • # of Trial APIs: 2